Sanofi reaffirmed earnings guidance for the year 2024. The company expects 2024 business EPS to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit at CER including the higher expected tax rate, barring unforeseen major adverse events.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.17 EUR | -1.19% | -5.47% | -0.66% |
May. 15 | Transcript : Sanofi Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
May. 14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.66% | 121B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi Reaffirms Earnings Guidance for the Year 2024